Jeffrey W. Bird, M.D., Ph.D.

Managing Director, Sutter Hill Ventures, Inc.

Jeff Bird, Ph.D., M.D., joined our Board in 2008. He has been a Managing Director of Sutter Hill Ventures, a venture capital firm, since 2002. Dr. Bird was a co-founder of Threshold, led the Company’s Series A financing in 2001, and was formerly a Threshold Board member from 2001 to 2004. Dr. Bird was previously Senior Vice President, Business Operations at Gilead Sciences, where he oversaw business development and commercial activities. Dr. Bird received a degree in Biological Sciences from Stanford in 1982, a Ph.D. in Cancer Biology in 1988 and a M.D. in 1992 from Stanford Medical School. Dr. Bird is currently a board member of a number of private biotechnology companies.

Bruce C. Cozadd

Chairman and Chief Executive Officer, Jazz Pharmaceuticals plc

Bruce Cozadd joined our Board of Directors in 2005. He has been the Executive Chairman of Jazz Pharmaceuticals since its inception in 2003 and, in April 2009, was named the Chairman and Chief Executive Officer of Jazz. Mr. Cozadd is also a member of the its Board of Directors. Prior to starting Jazz Pharmaceuticals, Mr. Cozadd served in various executive management positions with ALZA Corporation from 1991 until its acquisition by Johnson & Johnson in 2001. At the time of the merger, Mr. Cozadd was serving as Executive Vice President and Chief Operating Officer of ALZA, with responsibility for research and development, manufacturing, and sales and marketing. Prior to joining ALZA, he was in the Corporate Finance Health Care group at Smith Barney, Harris Upham & Co. Inc. He serves on the boards of Cerus Corporation, The Nueva School, and SFJAZZ.

David R. Hoffmann

Chief Executive Officer, Hoffmann Associates

David R. Hoffmann joined the Company’s board of directors in April 2007. Mr. Hoffmann also serves as a Director of DURECT Corporation. In 2002, Mr. Hoffmann retired from ALZA Corporation where his most recent position was Vice President and Treasurer. Mr. Hoffmann has over 30 years of experience in the finance and accounting fields and has held numerous management and senior executive management positions at ALZA. Mr. Hoffmann was with ALZA for more than 25 years where his principal areas of responsibility included serving as a strategist and manager of cash portfolios, an executive or financial officer of related companies and subsidiaries, implementation of corporate financing arrangements, and organizing and establishing international companies. Mr. Hoffmann holds a B.S. in Business Administration (accounting emphasis) from the University of Colorado. He has also served as a member of the Board of Directors of several ALZA subsidiaries including ALZA Development Company, ALZA Ireland Holdings Ltd., Therapeutic Discovery Corporation and Crescendo Pharmaceutical Corporation.

Wilfred E. Jaeger, M.D.

Partner, Three Arch Partners

Wilfred E. Jaeger, M.D., has served as a member of our Board of Directors since 2001. He has been a Partner of Three Arch Partners, a venture capital firm, since 1993. Dr. Jaeger serves as a Director of a number of private companies. He received his B.S. from the University of British Columbia, his M.D. from the University of British Columbia School of Medicine and his M.B.A. from Stanford University.


George G. C. Parker, Ph.D.

Dean Witter Distinguished Professor of Finance and Management,
Graduate School of Business,
Stanford University

George G.C. Parker, Ph.D. has served as a member of our board of directors since October 2004. Dr. Parker is the Dean Witter Distinguished Professor of Finance and Management and previously Senior Associate Dean for Academic Affairs and Director of the MBA Program, Graduate School of Business, Stanford University. He serves as a director of Continental Airlines, Inc., Affinity Group International, Inc., BGI Mutual Funds, Tejon Ranch Company, Converium Holding AG and First Republic Bank. Dr. Parker received his B.A. from Haverford College and his M.B.A. and Ph.D. from Stanford University.


David R. Parkinson, M.D.

Venture Partner, New Enterprise Associates

David R. Parkinson, M.D., joined our Board of Directors in 2010. He is a venture partner at New Enterprise Associates (NEA). From 2007 until 2012, Dr. Parkinson served as President and CEO of Nodality, a South San Francisco-based biotechnology company focused on the biological characterization of signaling pathways in patients with malignancy to enable more effective therapeutics development and clinical decision-making. Prior to 2007, Dr. Parkinson was senior vice president of Oncology Research and Development at Biogen Idec, vice president of Oncology Development at Amgen and vice president of Global Clinical Oncology Development at Novartis. Dr. Parkinson also worked at the National Cancer Institute from 1990 to 1997, serving as chief of the Investigational Drug Branch, then as acting associate director of the Cancer Therapy Evaluation Program. He has also held academic positions at the M.D. Anderson Cancer Center, University of Texas and New England Medical Center of Tufts University School of Medicine. Dr. Parkinson received his M.D. as gold medalist from the University of Toronto Faculty of Medicine in 1977, with Internal Medicine and Hematology/Oncology training in Montreal at McGill University and in Boston at New England Medical Center. Dr. Parkinson is a past chairman of the Food & Drug Administration (FDA) Biologics Advisory Committee and is a recipient of the FDA's Cody Medal. He is a past president of the International Society of Biological Therapy, and past editor of the Journal of Immunotherapy. He currently serves on the National Cancer Policy Forum of the Institute of Medicine. He has recently completed a term on the FDA's Science Board as well as a term on the Board of Directors of the American Association of Cancer Research (AACR). He continues to serve as Chairman of the AACR Finance Committee.


Harold E. "Barry" Selick, Ph.D.

Chief Executive Officer, Threshold Pharmaceuticals, Inc.

Harold E. "Barry" Selick, Ph.D. joined Threshold as Chief Executive Officer in June 2002. Between June 2002 and July 2007, Dr. Selick was a Venture Partner of Sofinnova Ventures, Inc., a venture capital firm. From January 1999 to April 2002, he was Chief Executive Officer of Camitro Corporation, a biotechnology company. From 1992 to 1999, he was at Affymax Research Institute, the drug discovery technology development center for Glaxo Wellcome plc, most recently as Vice President of Research. Prior to working at Affymax he held scientific positions at Protein Design Labs, Inc. and Anergen, Inc. As a staff scientist at Protein Design Labs, he co-invented the technology underlying the creation of fully humanized antibody therapeutics and applied that to PDL's first product, Zenapax, which was developed and commercialized by Roche for treating kidney transplant rejection. Dr. Selick received his B.S. and Ph.D. from the University of Pennsylvania and was a Damon Runyon-Walter Winchell Cancer Fund Fellow and an American Cancer Society Senior Fellow at the University of California, San Francisco.